{"paper_id":"cfcfb670-72d2-4a50-9914-fb45add5d0a8","body_text":"DEPARTMENTS: Response to Letter\nRassier, Sarah L. Cohen MD, MPH; Thao, Viengneesee PhD, MS; Borah, Bijan PhD; Farland, Leslie V. ScD; Laughlin-Tommaso, Shannon K. MD; Khan, Zaraq MBBS; Coutinho, Thais D. MD; Stewart, Elizabeth A. MD\nMayo Clinic, Rochester, Minnesota\nUniversity of Arizona, Tucson, Arizona\nMayo Clinic, Rochester, Minnesota\nFinancial Disclosure Elizabeth A. Stewart has received grants for her institution from the Agency for Healthcare Research and Quality/Patient-Centered Outcome Research (P50HS23418), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health (R01HD105714, R01HD109127-01A1 and P50HD115283); has received consulting fees from AbbVie, Anylyn, and ASKA pharmaceuticals; support for service on a DSMB from Myovant (now Sumitomo Pharma), holds a patent for Methods and Compounds for Treatment of Abnormal Uterine Bleeding which has no commercial activity; has received royalties from UpToDate; has received fees for developing educational content from the MED-IQ, Physicians' Education Resource, Omnia Education, Omnicuris and WebMD; and serves as an unpaid advisor to The Fibroid Foundation and the unpaid treasurer of the International Gynecologic Society. Bijan Borah reports receiving payments from Boeinger-Ingelheim. Shannon K. Laughlin-Tommaso has received royalties from UpToDate. Sarah L. Cohen Rassier has received royalites from UpToDate. The other authors did not report any potential conflicts of interest.","source_license":"CC0","license_restricted":false}